Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 134

1.

A multicentre prospective clinical trial of 68Gallium PSMA HBED-CC PET-CT restaging in biochemically relapsed prostate carcinoma: Oligometastatic rate and distribution, compared to standard imaging.

McCarthy M, Francis R, Tang C, Watts J, Campbell A.

Int J Radiat Oncol Biol Phys. 2019 Mar 16. pii: S0360-3016(19)30370-0. doi: 10.1016/j.ijrobp.2019.03.014. [Epub ahead of print]

PMID:
30890448
2.

Extent of disease in recurrent prostate cancer determined by [(68)Ga]PSMA-HBED-CC PET/CT in relation to PSA levels, PSA doubling time and Gleason score.

Verburg FA, Pfister D, Heidenreich A, Vogg A, Drude NI, Vöö S, Mottaghy FM, Behrendt FF.

Eur J Nucl Med Mol Imaging. 2016 Mar;43(3):397-403. doi: 10.1007/s00259-015-3240-1. Epub 2015 Nov 12.

PMID:
26563121
3.

68Ga-PSMA-HBED-CC PET/CT imaging in Black versus White South African patients with prostate carcinoma presenting with a low volume, androgen-dependent biochemical recurrence: a prospective study.

Lengana T, van de Wiele C, Lawal I, Maes A, Ebenhan T, Boshomane T, Zeevaart JR, Ankrah A, Mokgoro N, Vorster M, Sathekge M.

Nucl Med Commun. 2018 Feb;39(2):179-185. doi: 10.1097/MNM.0000000000000791.

PMID:
29257006
4.

Could 68-Ga PSMA PET/CT become a new tool in the decision-making strategy of prostate cancer patients with biochemical recurrence of PSA after radical prostatectomy? A preliminary, monocentric series.

De Bari B, Mazzola R, Aiello D, Fersino S, Gregucci F, Alongi P, Nicodemo M, Cavalleri S, Salgarello M, Alongi F.

Radiol Med. 2018 Sep;123(9):719-725. doi: 10.1007/s11547-018-0890-7. Epub 2018 Apr 23.

PMID:
29687208
5.

Comparison of [(18)F]DCFPyL and [ (68)Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer.

Dietlein M, Kobe C, Kuhnert G, Stockter S, Fischer T, Schomäcker K, Schmidt M, Dietlein F, Zlatopolskiy BD, Krapf P, Richarz R, Neubauer S, Drzezga A, Neumaier B.

Mol Imaging Biol. 2015 Aug;17(4):575-84. doi: 10.1007/s11307-015-0866-0.

6.

PSA-Stratified Performance of 18F- and 68Ga-PSMA PET in Patients with Biochemical Recurrence of Prostate Cancer.

Dietlein F, Kobe C, Neubauer S, Schmidt M, Stockter S, Fischer T, Schomäcker K, Heidenreich A, Zlatopolskiy BD, Neumaier B, Drzezga A, Dietlein M.

J Nucl Med. 2017 Jun;58(6):947-952. doi: 10.2967/jnumed.116.185538. Epub 2016 Dec 1.

7.

Intrapatient Comparison of 111In-PSMA I&T SPECT/CT and Hybrid 68Ga-HBED-CC PSMA PET in Patients With Early Recurrent Prostate Cancer.

Rauscher I, Maurer T, Souvatzoglou M, Beer AJ, Vag T, Wirtz M, Weirich G, Wester HJ, Gschwend JE, Schwaiger M, Schottelius M, Eiber M.

Clin Nucl Med. 2016 Sep;41(9):e397-402. doi: 10.1097/RLU.0000000000001273.

PMID:
27276206
8.

Detection level and pattern of positive lesions using PSMA PET/CT for staging prior to radiation therapy.

Schmidt-Hegemann NS, Fendler WP, Buchner A, Stief C, Rogowski P, Niyazi M, Eze C, Li M, Bartenstein P, Belka C, Ganswindt U.

Radiat Oncol. 2017 Nov 10;12(1):176. doi: 10.1186/s13014-017-0902-0.

9.

Clinical utility of (18)F-fluorocholine positron-emission tomography/computed tomography (PET/CT) in biochemical relapse of prostate cancer after radical treatment: results of a multicentre study.

Rodado-Marina S, Coronado-Poggio M, García-Vicente AM, García-Garzón JR, Alonso-Farto JC, de la Jara AC, Maldonado-Suárez A, Rodríguez-Fernández A.

BJU Int. 2015 Jun;115(6):874-83. doi: 10.1111/bju.12953. Epub 2015 Jan 21.

10.

Combined Early and Late [68Ga]PSMA-HBED-CC PET Scans Improve Lesion Detectability in Biochemical Recurrence of Prostate Cancer with Low PSA Levels.

Hohberg M, Kobe C, Täger P, Hammes J, Schmidt M, Dietlein F, Wild M, Heidenreich A, Drzezga A, Dietlein M.

Mol Imaging Biol. 2019 Jun;21(3):558-566. doi: 10.1007/s11307-018-1263-2.

PMID:
30105521
11.

Value of 68Ga-PSMA HBED-CC PET for the Assessment of Lymph Node Metastases in Prostate Cancer Patients with Biochemical Recurrence: Comparison with Histopathology After Salvage Lymphadenectomy.

Rauscher I, Maurer T, Beer AJ, Graner FP, Haller B, Weirich G, Doherty A, Gschwend JE, Schwaiger M, Eiber M.

J Nucl Med. 2016 Nov;57(11):1713-1719. Epub 2016 Jun 3.

12.

PSA levels, PSA doubling time, Gleason score and prior therapy cannot predict measured uptake of [68Ga]PSMA-HBED-CC lesion uptake in recurrent/metastatic prostate cancer.

Verburg FA, Pfister D, Drude NI, Mottaghy FM, Behrendt FF.

Nuklearmedizin. 2017;56(6):225-232. doi: 10.3413/Nukmed-0917-17-07. Epub 2018 Jan 11.

PMID:
29044297
13.

(68)Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate?

Ceci F, Uprimny C, Nilica B, Geraldo L, Kendler D, Kroiss A, Bektic J, Horninger W, Lukas P, Decristoforo C, Castellucci P, Fanti S, Virgolini IJ.

Eur J Nucl Med Mol Imaging. 2015 Jul;42(8):1284-94. doi: 10.1007/s00259-015-3078-6. Epub 2015 May 15.

PMID:
25975367
14.

68Ga-PSMA-11 PET/CT in recurrent prostate cancer: efficacy in different clinical stages of PSA failure after radical therapy.

Ceci F, Castellucci P, Graziani T, Farolfi A, Fonti C, Lodi F, Fanti S.

Eur J Nucl Med Mol Imaging. 2019 Jan;46(1):31-39. doi: 10.1007/s00259-018-4189-7. Epub 2018 Oct 22.

PMID:
30350010
15.

Detection rate of PET/CT in patients with biochemical relapse of prostate cancer using [68Ga]PSMA I&T and comparison with published data of [68Ga]PSMA HBED-CC.

Berliner C, Tienken M, Frenzel T, Kobayashi Y, Helberg A, Kirchner U, Klutmann S, Beyersdorff D, Budäus L, Wester HJ, Mester J, Bannas P.

Eur J Nucl Med Mol Imaging. 2017 Apr;44(4):670-677. doi: 10.1007/s00259-016-3572-5. Epub 2016 Nov 28.

PMID:
27896369
16.

68Ga-labelled PSMA ligand HBED-CC PET/CT imaging in patients with recurrent prostate cancer.

Akdemir EN, Tuncel M, Akyol F, Bilen CY, Baydar DE, Karabulut E, Ozen H, Caglar M.

World J Urol. 2019 May;37(5):813-821. doi: 10.1007/s00345-018-2460-y. Epub 2018 Aug 27.

PMID:
30151600
17.

68Ga-PSMA-11 PET/CT Mapping of Prostate Cancer Biochemical Recurrence After Radical Prostatectomy in 270 Patients with a PSA Level of Less Than 1.0 ng/mL: Impact on Salvage Radiotherapy Planning.

Calais J, Czernin J, Cao M, Kishan AU, Hegde JV, Shaverdian N, Sandler K, Chu FI, King CR, Steinberg ML, Rauscher I, Schmidt-Hegemann NS, Poeppel T, Hetkamp P, Ceci F, Herrmann K, Fendler WP, Eiber M, Nickols NG.

J Nucl Med. 2018 Feb;59(2):230-237. doi: 10.2967/jnumed.117.201749. Epub 2017 Nov 9.

18.

Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients.

Afshar-Oromieh A, Holland-Letz T, Giesel FL, Kratochwil C, Mier W, Haufe S, Debus N, Eder M, Eisenhut M, Schäfer M, Neels O, Hohenfellner M, Kopka K, Kauczor HU, Debus J, Haberkorn U.

Eur J Nucl Med Mol Imaging. 2017 Aug;44(8):1258-1268. doi: 10.1007/s00259-017-3711-7. Epub 2017 May 12. Erratum in: Eur J Nucl Med Mol Imaging. 2017 Sep;44(10 ):1781.

19.

Simultaneous 68Ga-PSMA HBED-CC PET/MRI Improves the Localization of Primary Prostate Cancer.

Eiber M, Weirich G, Holzapfel K, Souvatzoglou M, Haller B, Rauscher I, Beer AJ, Wester HJ, Gschwend J, Schwaiger M, Maurer T.

Eur Urol. 2016 Nov;70(5):829-836. doi: 10.1016/j.eururo.2015.12.053. Epub 2016 Jan 18.

PMID:
26795686
20.

A Prospective, Multi-site, International Comparison of F-18 fluoro-methyl-choline, multi-parametric magnetic resonance and Ga-68 HBED-CC (PSMA-11) in men with High-Risk Features and Biochemical Failure after Radical Prostatectomy: Clinical Performance and Patient Outcomes.

Emmett L, Metser U, Bauman G, Hicks RJ, Weickhardt A, Davis ID, Punwani S, Pond GR, Chua SS, Ho B, Johnston E, Pouliot F, Scott A.

J Nucl Med. 2018 Nov 15. pii: jnumed.118.220103. doi: 10.2967/jnumed.118.220103. [Epub ahead of print]

PMID:
30442757

Supplemental Content

Support Center